A REVIEW STUDY ON: TARGETED DRUGS IN TUMOR THERAPY

Abstract

Background: Cancer continues to be a global health challenge, accounting for a significant portion of global mortality.Although focused treatment plans preserve promise for personalised most cancers treatments. Methodology: RI techniques are appealing in clinical practice for early treatment response assessment and patient prognosis. Photoacoustic imaging (PAI) is a new noninvasive molecular imaging modality that uses the photoacoustic effect to generate an ultrasound signal. Results: One biomarker that doctors look for in non-small cell lung cancer is a mutation in the EGFR gene. Combinations of cetuximab and TKI are safe. Following EGFR-TKI resistance in NSCLC, combining an anti-EGFR mAb with an EGFR-TKI resulted in expected safety findings. Conclusions: The use of molecular imaging to predict the efficacy of cancer-targeted therapy early on.targeted therapies have emerged as a promising treatment option for a variety of cancers, including lung cancer, colorectal cancer, and prostate cancer. The discovery of specific molecular targets in cancer cells has resulted in the development of a wide range of targeted drugs that selectively inhibit key pathways involved in tumour growth and progression.